Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16510912 | 0.81 | ALDH1A1 (0.33) | — | |
| SCHEMBL3818212 | 0.79 | KDM4E (0.36) | — | |
| SCHEMBL15556458 | 0.78 | — | — | |
| SCHEMBL4949048 | 0.78 | PDK2 (0.32) | PDK2 | |
| SCHEMBL3277032 | 0.77 | GAA (0.39) | — | |
| SCHEMBL29572357 | 0.71 | — | — | |
| SCHEMBL28733846 | 0.71 | — | — | |
| SCHEMBL5844067 | 0.70 | PDK2 (0.37) | PDK2 | |
| SCHEMBL782788 | 0.70 | ALDH1A1 (0.36) | — | |
| SCHEMBL6026300 | 0.69 | KDM4E (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113801114-B | Fused bicyclic heteroaryl derivative, preparation method and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-114539245-A | Pyrimidine-fused ring derivative-containing regulator, and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-113801114-A | Fused bicyclic heteroaryl derivative, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2021-12-17 | — | — | CN | disclosed |
| US-9593121-B2 | Indole substituted pyrrolopyrimidinyl inhibitors of Uba6 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593121-B2 | Indole substituted pyrrolopyrimidinyl inhibitors of Uba6 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593121-B2 | Indole substituted pyrrolopyrimidinyl inhibitors of Uba6 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| EP-3036228-A1 | NEW 6-ALKYNYL PYRIDINE | Boehringer Ingelheim International GmbH (DE) | 2016-06-29 | — | — | EP | disclosed |
| US-20150210700-A1 | INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF UBA6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150210700-A1 | INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF UBA6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150210700-A1 | INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF UBA6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-30 | — | — | US | disclosed |
| EP-2879681-A1 | INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF Uba6 | Millennium Pharmaceuticals, Inc. (US) | 2015-06-10 | — | — | EP | disclosed |
| WO-2015025019-A1 | NEW 6-ALKYNYL PYRIDINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-26 | — | — | WO | disclosed |
| WO-2014022744-A1 | INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF Uba6 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-06 | — | — | WO | disclosed |
| WO-2011152485-A1 | NOVEL 4,5-FUSED PYRIMIDINE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2011-12-08 | — | — | WO | disclosed |
| EP-1383747-B1 | FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) | GLAXO GROUP LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| US-7279474-B2 | Substituted pyrrolo[2,3-d]pyrimidines as antagonists of the corticotropin releasing factor (CRF) | GLAXO GROUP LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | GLAXO GROUP LIMITED (GB) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | CRH, CRHR1, CRHR2 | PDK2 1949/4885PDK4 2564/4885 |
| US-20150210700-A1 | INDOLE-SUBSTITUTED PYRROLOPYRIMIDINYL INHIBITORS OF UBA6 | UBA6, UBE2V1, UBA1 | PDK2 3269/4885PDK4 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.